Every two minutes, a man is diagnosed with prostate cancer in our country. This disease is currently the second-leading cancer-related killer of men in the United States.

Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment ...

Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now ...

Surface-enhanced Raman spectroscopy (SERS) is revolutionizing biomedical diagnostics and therapeutics, enabling breakthroughs ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Curium introduces innovative 18F-PSMA PET radiopharmaceutical, Pylclari to treat prostate cancer in Estonia, Finland, Latvia, & Sweden: Paris, France Wednesday, January 29, 2025, ...

In addition, indirect methods such as DNA or antigens detection should be validated or improved, respectively, making them more easily available even in small facilities. The increase of ...

YOLO is a popular one-stage object detection model known for its speed and accuracy. It processes images in real-time, making it suitable for applications requiring quick detection. EfficientDet is ...

Giles Coren, esteemed restaurant critic and writer, has come forward with his prostate cancer diagnosis amid a surge in ...

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

While one in eight men are diagnosed with prostate cancer in their lifetime, the VA says for veterans, it's much higher.